Dynavax shares spike on promising Heplisav data

Shares of Dynavax Technologies soared 35 percent after the developer announced that its hepatitis B vaccine Heplisav produced promising data in a mid-stage study, protecting patients with chronic kidney disease at week 24.

It was a small trial, enrolling 41 patients aged 40 to 70 suffering from a progressive loss of renal function. Researchers tested two different doses of the closely-watched vaccine. The vaccine, now in late-stage studies, protected all dialysis and pre-dialysis patients.

"Chronic kidney disease patients undergoing hemodialysis are at high risk of HBV infection, are hyporesponsive to current HBV vaccines, and have a worse prognosis if infected with HBV," commented Tyler Martin, M.D., Dynavax's chief medical officer. "These results demonstrate that Heplisav can effectively protect this susceptible patient population."

- see the Dynavax's release
- here's the Reuters story

Suggested Articles

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.

Ebola has claimed thousands of lives in recent outbreaks, but now the world has a licensed vaccine option in Merck's Ervebo.

Cosette Pharmaceuticals which was formed in December with a deal for dermatology projects has gone back to G&W Labs for a liquids plant.